MAP2K7 and neoplasm: In combination with our findings, this indicates that simultaneous loss-of-function mutations or deletions of the tumor suppressors SUZ12 and NF1 might be a marker for the clinical use of molecular targeted drugs against MPNSTs that inhibit the RAS-MAPK pathway, for example MEK inhibitors such as Trametinib, Cobimetinib, and Binimetinib.